ID   HLC-1
AC   CVCL_5529
SY   HLC1
DR   CLO; CLO_0050024
DR   BioSample; SAMN03472335
DR   cancercelllines; CVCL_5529
DR   Cell_Model_Passport; SIDM01805
DR   Cosmic; 1154601
DR   DepMap; ACH-001088
DR   GEO; GSM784262
DR   PharmacoDB; HLC1_547_2019
DR   Progenetix; CVCL_5529
DR   RCB; RCB0083
DR   Wikidata; Q54889842
RX   PubMed=140093;
RX   PubMed=3518877;
RX   PubMed=3986962;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~33 hours (Note=At 29th passage) (PubMed=140093).
CC   Genome ancestry: African=4.37%; Native American=0%; East Asian, North=90.08%; East Asian, South=3.53%; South Asian=0%; European, North=0%; European, South=2.02% (PubMed=30894373).
CC   Caution: Indicated by Riken to originate from Okabe T. but with no reference provided. Therefore it is not certain that HLC-1 from Riken and HLC-1 originating from Akagi T. and Kimoto T. (PubMed=140093) are identical.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): RCB
ST   Amelogenin: X
ST   CSF1PO: 7,12
ST   D13S317: 8
ST   D16S539: 9,12
ST   D5S818: 9,10
ST   D7S820: 11,13
ST   TH01: 7,9
ST   TPOX: 12
ST   vWA: 16,17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=140093; DOI=10.20772/cancersci1959.67.4_483;
RA   Akagi T., Kimoto T.;
RT   "Establishment and characteristics of a human lung adenocarcinoma cell
RT   line.";
RL   Gann 67:483-492(1976).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3986962; DOI=10.1093/carcin/6.4.549;
RA   Watatani M., Ikenaga M., Hatanaka T., Kinuta M., Takai S.-i., Mori T.,
RA   Kondo S.;
RT   "Analysis of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced DNA
RT   damage in tumor cell strains from Japanese patients and demonstration
RT   of MNNG hypersensitivity of Mer xenografts in athymic nude mice.";
RL   Carcinogenesis 6:549-553(1985).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//